Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas
Madrid, EspañaPublications in collaboration with researchers from Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (112)
2024
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5
2023
-
Comprehensive analysis of epigenetic and epitranscriptomic genes’ expression in human NAFLD
Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 901-924
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
-
Impact of body composition in advanced hepatocellular carcinoma: A subanalysis of the SORAMIC trial
HEPATOLOGY COMMUNICATIONS, Vol. 7, Núm. 6
-
Mapping early serum proteome signatures of liver regeneration in living donor liver transplant cases
BioFactors, Vol. 49, Núm. 4, pp. 912-927
-
Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879
-
Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial
Journal of Clinical Oncology
2022
-
A new animal model of atrophy–hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits
Scientific Reports, Vol. 12, Núm. 1
-
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693
-
DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis
Cancers, Vol. 14, Núm. 9
-
Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood
Bioengineering and Translational Medicine, Vol. 7, Núm. 3
-
Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies
Advances in Cancer Research (Academic Press Inc.), pp. 367-413
-
Liver diseases: a sanitary and social challenge for Europe in the XXI Century. Results of EASL-Lancet Comission
Medicina Clinica
-
Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease
Journal of Physiology and Biochemistry, Vol. 78, Núm. 1, pp. 229-243
-
Neoantigens as potential vaccines in hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 2
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures
Gut, Vol. 71, Núm. 6, pp. 1141-1151
-
Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study
Journal for immunotherapy of cancer, Vol. 10, Núm. 11
-
The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality
The Lancet, Vol. 399, Núm. 10319, pp. 61-116